About Us

About Cytoimmune Therapeutics

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market. Currently we are developing our proprietary Chimeric Antigen Receptor (CAR) engineered NK cells (CAR-NK) technology, which we licensed from the laboratories of Drs. Michael Caligiuri and Jianhua Yu at the City of Hope National Medical Center (COH).

Leadership

Richard
Experience:
  • NetJets (Berkshire Hathaway Company)
  • Founder, President, CEO, Milestone Aviation Group
  • Pioneered the concept of fractional jet ownership

Rich Santulli, was the founder and chairman of Milestone Aviation Group, a helicopter and business jet leasing company. He is best known for pioneering the concept of fractional jet ownership with NetJets, a company he developed in 1986. Santulli was once considered a possible successor to Warren Buffett at Berkshire Hathaway.

MichaelACaligiuriMD
Experience:
  • President, City of Hope National Medical Center
  • Deana and Steve Campbell Physician-in-Chief Distinguished Chair
  • Past President, AACR
  • Elected to National Academy of Medicine for breakthrough human NK cell and T cell discoveries

Michael A. Caligiuri, M.D., is the President of the City of Hope Natonal Medical Center and holds the Deana and Steve Campbell Physician-in-Chief Distinguished Chair. He is a world-renowned physician, scientist, builder, innovator, leader and visionary. Dr. Caligiuri is dedicated to developing the next generation of leading-edge immune therapies for cancer, rapidly delivering them to patients and ultimately curing the disease.

Prior to joining City of Hope, Dr. Caligiuri worked for 20 years as a physician, scientist and leader in the cancer program at The Ohio State University. He spent the past decade as CEO of The James Cancer Hospital and Solove Research Institute and directed The Ohio State University Comprehensive Cancer Center for 14 years, recruiting over 300 cancer physicians and scientists and building the 3rd largest cancer hospital in America.

Dr. Caligiuri has spent the last 35 years studying human natural killer (NK) cell biology during which time he made several seminal discoveries that have paved the way for CAR NK cells to advance into the clinic. He has over 400 peer-reviewed original research publications on NK cells and/or cancer. Over 1,000 patients have been treated on clinical trials designed or co-designed by Dr. Caligiuri to modulate NK cells for cancer therapy.

Dr. Caligiuri is the past president (2018) of the American Association for Cancer Research (AACR), the world’s largest cancer research organization with 40,000 members in 120 countries. He was elected as a Fellow to the AACR Academy, received a lifetime achievement award from Stanford University School of Medicine and was elected to the US National Academy of Medicine for his basic and translational work on human NK cells and cancer.

Aleksey-Krylov
Experience:
  • Multiple fundraising and exit deals
  • Emerging biotech and pubco CFO

Aleksey Krylov is a strategic CFO to life sciences companies with the background in private equity investing. Most recently, he served as a Chief Financial Officer of DIH International, Ltd., a Swiss-Chinese medical equipment manufacturer with $80m in sales and 400 employees globally.

Previously, he was an Chief Financial Officer of SELLAS Life Sciences, Inc. (NASDAQ: SLS, peak market cap ~$170m), an oncology immuno-therapeutics company. At SELLAS he led the reverse merger of private SELLAS into a publicly listed target and raised $10.7 million in financing. At both companies, he was responsible for managing financial, investor relations and administrative operations of the company.

Prior to becoming CFO, Mr. Krylov was a family office investment professional with a focus on M&A, capital raising, private equity investing and restructuring. His industries of interest included life sciences, medical technologies, healthcare IT and consumer products, among others.

Krylov began his career with SG Cowen’s equity capital markets group as an investment banking analyst in 2002. Mr. Krylov holds an M.B.A. from Columbia Business School and a B.S. in Business Administration from Babson College. He is a CFA charterholder.

William-Rosellini
Experience:
  • 5 exits, 3 public offerings (OTC:QB “NXNN”), (TSX.V “PINK”), (NYSE:”DSS”)

Rosellini is the President of CytoImmune Therapeutics. Previously, Rosellini was the CEO of Perimeter Medical, Inc. He also led Nexeon Medsystems, Inc., a medical device manufacturing company that went public in 2017. Before that he founded and led Lexington Technology Group, LLC, a database company commercializing a electronic health record database solution to an exit (“DSS” NYSE).

Before that he founded Sarif Biomedical LLC, a stereotactic cancer microsurgery with IP spun-out of Medtronic and led company to an exit with Marathon Patent Group, Inc. (“MARA” NSDQ). He subsequently served on the Marathon board of directors and chaired the Audit committee. Rosellini completed 2 acquisitions to form Telemend Medical, Inc. a clinical engineering services company and led that company to an exit in 2016. Rosellini was also CEO at Microtransponder, an implantable neurostimulation developer with solutions for stroke rehabilitation. He is a former minor league pitcher with the Diamondbacks of the Arizona League, holds a JD, MBA, MS of Accounting, MS of Computational Biology, MS of Neuroscience and MS of Regulatory Science.

Robert-Salcedo
Experience:
  • 25+ years experience in biotech & cell therapy
  • Led facility development & technical transfer for Amgen Puerto Rico

Robert Salcedo comes with over 25 years of experience in biotechnology. Has worked for both Amgen and Genentech in leadership roles. He has also lead a start-up biosimilar company which developed and filed multiple applications in both US and EU. He is the co-founder of BiosciencesCorp and Biosimilar solutions which are dedicated to helping both Biotech companies and Biosimilar companies develop their strategy and bring products to commercialization.

Lei-Zhang
Experience:
  • Manager, Gel Elelectrophoretic and Pathway Analysis Services
  • Research Fellow, Department of Cellular and Molecular Biology at City of Hope
  • Postdoctoral scholar, Department of Pathology and Laboratory Medicine at University of Kentucky

Accomplished, bilingual, medical research professional with a solid history of success performing extensive research to provide valuable diagnoses; positioned to excel in demanding pharmaceutical and biotechnology research environment. Extensive medical, pharmacological, and administrative knowledge complemented by advanced study and practice in protein analysis, immunology and oncology. Proven resource planning and cost reduction skills to ensure adherence to standard medical research practices while meeting target objectives. Expert in nurturing an excellent relationship with everyone within the organizational premises . Providing Services with a core value of Sense of Urgency. Technical proficiency in Multiple Bioinformatics data analysis, MetaCore Enrichment Analysis, Ingenuity Pathway Analyses (IPA) , DAVID Bioinformatics Resources , STRING Database functional protein association networks Analysis, Adobe Photoshop, TotalLab Samespot, PDQuest Advanced, Spectrometer, Mascot, Proteome Discoverer, Progenesis QI, Flowjo and MS Office.

Kamali-Chance
Experience:
  • CEO & Executive Consultant, KC Biopharma Consulting
  • Senior Director of Global Regulatory Strategy/Global Regulatory Affairs, Quintiles, Inc.
  • US Director of Regulatory Affairs, Synthon BV

She spearheads biosimilar regulatory strategy and interactions with regulators for development of biosimilars in highly regulated markets as well as emerging markets.

Dr. Chance has provided global regulatory strategy for number of biosimilar products in development including biosimilars of Enbrel, Remicade, Herceptin, Rituxin/Mabthera, Humira, Avastin, Epogen, Lucentis, Aranesp, Recombinant Insulins, Neupogen/Neulasta, among others.

Dr. Chance has over 25 years of work experience in the healthcare industry, including the last 19 years in regulatory strategy/affairs at CRO, pharmaceutical and biotechnology industries. Dr. Chance has a Ph.D in Nutrition/Nutritional.

barbaraaraneo-headshot
Experience:
  • Founder and CEO, Times Life Science Consulting, LLC
  • Program Manager, Technology Commercialization, Utah Science Technology and Research (USTAR)
  • Director Strategy and Sourcing – Diabetes, Novo Nordisk A/S
  • Director, Juvenile Diabetes Research Foundation
  • VP, StemCells, Inc.
  • SVP Research, PHARMADIGM

Barbara Araneo, Ph.D., serves as VP of Clinical Affairs. Previously she served at Novo Nordisk, Inc as a Director in External Innovation Sourcing, a unit linked to Novo Nordisk’s Global Research Department. Previously, she was a member of the JDRF Research team as the Director of the Diabetes Complications Therapeutic Area, where her role was to create and manage a portfolio of externally funded research grants aimed at translation of primary discovery along the path of new therapeutics and biomarkers.

Dr. Araneo served on the faculty of the University of Utah’s Department of Pathology as Associate Professor and has over 70 publications and 30 patents. In addition to her academic career, Dr. Araneo was Vice President of Development at StemCells Inc., where she was responsible for directing the effort to bring the company’s neural cell-based product candidate from the exploratory and preclinical proof of principle stages into clinical development under the FDA regulatory process. Prior to joining StemCells, Dr. Araneo was a Scientific Co-Founder and Senior Vice President of Research and Development at Pharmadigm, a privately held biopharmaceutical company with a number of products discovered at the company and developed for various stages of clinical development for inflammatory conditions. Over her career Dr. Araneo specialized in translational research concentrating on bringing disease-modifying targets through validation and drug proof of concept. She has led project teams to enable filing of INDs, communicate with the FDA and initiate first in man clinical trials. Dr. Araneo obtained her doctorate in Cellular Immunology from the University of Rochester and completed postdoctoral training at Washington University School of Medicine and the Department of Microbiology at UCLA. In addition to a doctorate degree, Dr. Araneo holds certification in US Regulatory Affairs.

Board of Directors

Richard

Rich Santulli, was the founder and chairman of Milestone Aviation Group, a helicopter and business jet leasing company. He is best known for pioneering the concept of fractional jet ownership with NetJets, a company he developed in 1986. Santulli was once considered a possible successor to Warren Buffett at Berkshire Hathaway.

William-Rosellini

Rosellini is the President of CytoImmune Therapeutics. Previously, Rosellini was the CEO of Perimeter Medical, Inc. He also led Nexeon Medsystems, Inc., a medical device manufacturing company that went public in 2017. Before that he founded and led Lexington Technology Group, LLC, a database company commercializing a electronic health record database solution to an exit (“DSS” NYSE). Before that he founded Sarif Biomedical LLC, a stereotactic cancer microsurgery with IP spun-out of Medtronic and led company to an exit with Marathon Patent Group, Inc. (“MARA” NSDQ). He subsequently served on the Marathon board of directors and chaired the Audit committee. Rosellini completed 2 acquisitions to form Telemend Medical, Inc. a clinical engineering services company and led that company to an exit in 2016. Rosellini was also CEO at Microtransponder, an implantable neurostimulation developer with solutions for stroke rehabilitation. He is a former minor league pitcher with the Diamondbacks of the Arizona League, holds a JD, MBA, MS of Accounting, MS of Computational Biology, MS of Neuroscience and MS of Regulatory Science.

Scientific Advisory Board

Jianhua-Yu

Jianhua Yu, Ph.D., has joined City of Hope as a professor in the Department of Hematology & Hematopoietic Cell Transplantation. He is a member of the Hematologic Malignancies and Stem Cell Transplantation Institute and founding director of the NK Cell Biology Research Program within the Center for T Cell Immunotherapy of the institute.

Yu’s research interests include NK cell biology, chimeric antigen receptor (CAR) NK cells, CAR T cells, oncolytic virus, bispecific antibodies, natural product-based therapeutics and hematopoietic stem cell transplantation. His lab focuses on both basic and translational research relevant to developing innovative cellular immunotherapy and oncolytic virotherapy for the treatment of cancers such as multiple myeloma, acute myeloid leukemia and glioblastoma.

Prior to joining City of Hope, Yu was a tenured professor in the Division of Hematology of the College of Medicine and the Comprehensive Cancer Center at The Ohio State University. Yu received his Ph.D. degree from Purdue University in 2003 and then moved to The Ohio State University for his postdoctoral training, where he subsequently accepted a junior faculty position and advanced through the tenure track.

Yu has authored or co-authored over 160 publications, many of the which are in high-impact journals, in the field of natural killer cell biology, cancer immunotherapy, oncolytic virotherapy, hematopoietic stem cell transplantation, etc. Work from Yu and his colleagues has also resulted in about 10 patents (awarded or pending).

In 2015, Yu received The Jack Latham Memorial Award for Innovative Research from the American Association of Blood Banks and the Janet D. Rowley Medical Award from Gabrielle’s Angel Foundation and FAME Faculty of the Year Award for researchers from College of Medicine at The Ohio State University. Yu is a scholar at several national research foundations including the National Blood Foundation Scholar and the Leukemia & Lymphoma Society.